XML 20 R8.htm IDEA: XBRL DOCUMENT v3.23.1
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Cash flows from operating activities:    
Net cash used in operating activities $ (50,257) $ (27,081)
Cash flows from investing activities:    
Proceeds from sale of property and equipment 9 1
Purchases of property and equipment (690) (2,185)
Purchases of equity securities (9,356) (29,333)
Purchases of available-for-sale debt securities (26,236) (57,163)
Proceeds from sales of equity securities 2,789 14,932
Proceeds from sales of available-for-sale debt securities 3,301 12,540
Maturities of available-for-sale debt securities 27,554 12,766
Net cash provided by (used in) investing activities (2,629) (48,442)
Cash flows from financing activities:    
Debt issuance costs paid 0 (100)
Preferred stock dividend (3) (3)
Common stock dividend (4,980) (5,029)
Purchase of treasury stock 0 (3,879)
Payments related to tax withholding for share-based compensation (314) (209)
Repayment of debt (368) (367)
Net cash provided by (used in) financing activities (5,665) (9,587)
Cash and cash equivalents and restricted cash and cash equivalents:    
Net increase (decrease) during the period (58,551) (85,110)
Balance, beginning of period 391,341 253,143
Balance, end of period 332,790 168,033
Cash and cash equivalents, and restricted cash and cash equivalents within the Consolidated Balance Sheets    
Cash and cash equivalents 330,155  
Restricted cash and cash equivalents [1] 2,635  
Total cash and cash equivalents and restricted cash and cash equivalents $ 332,790 $ 168,033
[1] See “—Note 5 (Insurance Operations)” for a discussion of the nature of the restrictions for restricted cash and cash equivalents.